# Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

> **NCT00141323** · PHASE3 · COMPLETED · sponsor: **Ligand Pharmaceuticals** · enrollment: 8556 (estimated)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** lasofoxifene
- **OTHER:** placebo
- **DRUG:** lasofoxifene

## Key facts

- **NCT ID:** NCT00141323
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 8556 (ESTIMATED)
- **Last updated:** 2011-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141323, "Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00141323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*